Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

OCUL stock hub

Ocular Therapeutix, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

OCULis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.1B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

OCUL

In the news

Latest news · OCUL

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-68.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-37.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All OCUL market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

206

Groups with data

Currency

USD

Showing 206 of 206 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001393434
Company name	Ocular Therapeutix, Inc.
Country	United States
Country code	US
Cusip	67576A100
Employees	325
Employees Change	51%
Employees Change Percent	18.61
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2014-07-25
Isin	US67576A1007
Last refreshed	2026-05-10
Market cap	$2.1B
Market cap category	Mid-Cap
Price	$9.65
Price currency	USD
Rev Per Employee	160,116.92x
Sector	Healthcare
Sic	2834
Symbol	OCUL
Website	https://www.ocutx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.75%
EV Sales Forward	25.22x
EV/Sales	29.32x
FCF yield	-11.4%
P/B ratio	3.63x
P/S ratio	40.6x
PS Forward	34.93x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-175.1M
Net Income	$-290.5M
Net Income Growth Years	0%
Pretax Margin	-558.24%
Profit Per Employee	$-893,840
ROA	-32.88
Roa5y	-25.86
ROCE	-43.72
ROE	-68.55
Roe5y	-80.17
ROIC	-37.31

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.51%
Cagr1y	36.91%
Cagr3y	15.58%
Cagr5y	-9.9%
EPS Growth Years	0
Revenue Growth	-12.76x
Revenue Growth Q	0.81x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	0.23x
Revenue Growth5 Y	18.64x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.09
Assets	$732.5M
Cash	$666.7M
Current Assets	$706M
Current Liabilities	$47.7M
Debt	$79.5M
Debt Equity	$0.14
Equity	$581.6M
Interest Coverage	-25.75
Liabilities	$151M
Long Term Assets	$26.5M
Long Term Liabilities	$103.3M
Net Cash	$587.2M
Net Cash By Market Cap	$27.79
Net Cash Growth	114.75%
Net Debt Equity	$-1.01
Tangible Book Value	$581.6M
Tangible Book Value Per Share	$2.66
WACC	9.45

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	14.81
Inventory Turnover	64.83
Net Working Capital	$-5.2M
Quick ratio	14.49
Working Capital	$658.3M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-19.87%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-5.02%
1Y total return	36.88%
200-day SMA	11
3Y total return	54.4%
50-day SMA	9.11
50-day SMA vs 200-day SMA	50under200
5Y total return	-40.62%
All Time High	44.19
All Time High Change	-78.16%
All Time High Date	2015-03-25
All Time Low	2
All Time Low Change	383.71%
All Time Low Date	2023-11-10
ATR	0.48
Beta	0.93
Beta1y	1.07
Beta2y	1.33
Ch YTD	-20.51
High	9.72
High52	16.44
High52 Date	2025-12-08
High52ch	-41.3%
Low	9.3
Low52	6.23
Low52 Date	2026-02-17
Low52ch	54.9%
Ma50ch	5.94%
Premarket Change Percent	-0.62
Premarket Price	$9.62
Premarket Volume	4,714
Price vs 200-day SMA	-12.27%
RSI	57.03
RSI Monthly	52.61
RSI Weekly	48.56
Sharpe ratio	0.73x
Sortino ratio	1.34
Total Return	-19.87%
Tr YTD	-20.51
Tr1m	15.71%
Tr1w	2.33%
Tr3m	5.35%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	4
Analyst Price Target Top	$22
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.32
Earnings Revenue Estimate	12,707,160x
Earnings Revenue Estimate Growth	18.78x
Operating Income	$-299.4M
Operating margin	-575.4
Price target	$24.2
Price Target Change	$151
Price Target Change Top	$128

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	216,603,291%
Float Percent	98.92%
Shares Insiders	1.08%
Shares Institutions	88.89%
Shares Out	218,960,358
Shares Qo Q	0.53%
Shares Yo Y	19.87%
Short Float	11.32%
Short Ratio	6.93
Short Shares	11.2

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-289.3M
Average Volume	2,851,463.65x
Bv Per Share	2.66
CAPEX	$-14.7M
Ch10y	-5.02
Ch1m	15.71
Ch1w	2.33
Ch1y	36.88
Ch3m	5.35
Ch3y	54.4
Ch5y	-40.62
Ch6m	-11.06
Change	-0.31%
Change From Open	0.31
Close	9.68
Days Gap	-0.62
Depreciation Amortization	4,625,000
Dollar Volume	20,236,185.1
Earnings Date	2026-05-05
Earnings Time	bmo
EBIT	$-299.4M
EBITDA	$-294.8M
EPS	$-1.45
F Score	2
FCF	$-240.9M
FCF EV Yield	-15.79x
FCF Per Share	$-1.1
Financing CF	557,832,000
Fiscal Year End	December
Founded	2,006
Investing CF	-14,609,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-05
Ma150	10.56
Ma150ch	-8.65%
Ma20	9.41
Ma20ch	2.57%
Net CF	317,018,000
Next Earnings Date	2026-08-04
Open	9.62
Optionable	Yes
Position In Range	83.33
Post Close	9.65
Postmarket Change Percent	-3.34
Postmarket Price	$9.33
Ppne	24,920,000
Pre Close	9.68
Price Date	2026-05-08
Ptbv Ratio	3.63
Relative Volume	0.74x
Revenue	52,038,000x
SBC By Revenue	92.84x
Share Based Comp	48,310,000
Tr6m	-11.06%
Us State	Massachusetts
Volume	2,097,014
Z Score	5.3

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does OCUL pay a dividend?

Capital-return profile for this ticker.

Performance

OCUL stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns OCUL?

Insider, institutional, and short-interest positioning.

Institutional ownership

+88.9%

Float: +98.9% of shares outstanding

Insider ownership

+1.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

OCUL momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

57.0

Neutral momentum band

Price vs 200-day MA

-12.3%

50/200-day relationship not available

Beta (5Y)

0.93

Moves roughly with the market

Sharpe ratio

0.73

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About OCUL

Hub-level FAQ points readers to the deeper analysis pages.

What is the current OCUL stock rating?

Ocular Therapeutix, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full OCUL analysis?

The full report lives at /stocks/OCUL/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for OCUL?

The latest report frames OCUL around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the OCUL page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.